Literature DB >> 22518241

Prevalence and clinical characteristics of intracerebral hemorrhages associated with clopidogrel.

Steve M Cordina1, Ameer E Hassan, Mustapha A Ezzeddine.   

Abstract

BACKGROUND: As clopidogrel is being increasingly used, intracerebral hemorrhage (ICH) associated with clopidogrel are expected to increase. We assessed the prevalence and clinical characteristics of of ICH with clopidogrel in a consecutive series of patients in two hospitals.
METHODS: We retrospectively reviewed the medication history of 204 patients (112 in one hospital and 92 in another - both individually consecutive) admitted with ICH. We identified the patients who were using clopidogrel prior to ICH occurrence. The etiology of the ICH was categorized on the basis of clinical history and diagnostic imaging, and outcome was subsequently evaluated.
RESULTS: A total of 8 (4%) of the 204 patients were using clopidogrel prior to onset of ICH. Clopidogrel was the only medication in 3 patients and was used with aspirin or warfarin in 3 and 2 patients, respectively. Aspirin or warfarin was the only medication in 23 (%) and 14 (%) patients associated with ICH, respectively. The hematoma was located in the basal ganglia (n=2), lobes (n=2), thalamus (n=1), intraventricular (n=2), and cerebellar (n=2). One patient had secondary intraventricular extension. All patients using a combination of clopidogrel and warfarin prior to ICH died.
CONCLUSION: The prevalence of ICH associated with clopidogrel is approximating the prevalence of aspirin- or warfarin-associated ICH. The mortality with clopidogrel related ICH appears to be high particularly when in combination with another antithrombotic agent.

Entities:  

Keywords:  Clopidogrel; aspirin; hypertension; intracerebral hemorrhage; intraventricular hemorrhage; mortality; neurological outcome; warfarin

Year:  2009        PMID: 22518241      PMCID: PMC3317332     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  14 in total

Review 1.  Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I--Pathophysiological and pharmacological features.

Authors:  A I Qureshi; A R Luft; M Sharma; L R Guterman; L N Hopkins
Journal:  Neurosurgery       Date:  2000-06       Impact factor: 4.654

2.  Aspirin-use before ICH: a potentially treatable iatrogenic coagulopathy?

Authors:  Stanley Tuhrim
Journal:  Stroke       Date:  2005-12-01       Impact factor: 7.914

3.  Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death.

Authors:  Pertti Saloheimo; Mikko Ahonen; Seppo Juvela; Juhani Pyhtinen; Eeva-Riitta Savolainen; Matti Hillbom
Journal:  Stroke       Date:  2005-12-01       Impact factor: 7.914

4.  Effect of oral antiplatelet agents on major bleeding in users of coumarins.

Authors:  Tom Schalekamp; Olaf H Klungel; Patrick C Souverein; Anthonius de Boer
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

Review 5.  Haemorrhagic stroke during anti-platelet therapy.

Authors:  M Cattaneo
Journal:  Eur J Anaesthesiol Suppl       Date:  2008

6.  Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab.

Authors:  Adnan I Qureshi; Mustafa Saad; Osama O Zaidat; Jose I Suarez; Michael J Alexander; M Fareed; K Suri; Zulfiqar Ali; L Nelson Hopkins
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

7.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack.

Authors:  Dawn M Meyer; Karen C Albright; Teresa A Allison; James C Grotta
Journal:  J Stroke Cerebrovasc Dis       Date:  2008 Jan-Feb       Impact factor: 2.136

9.  High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study.

Authors:  Adnan I Qureshi; Jawad F Kirmani; Adnan Safdar; Shafiuddin Ahmed; Muhammad A Sayed; Ravi U Pande; Richard Ferguson; Linda A Hershey; Khalid J Qazi
Journal:  Pharmacotherapy       Date:  2006-04       Impact factor: 4.705

10.  Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

Authors:  Jeff S Healey; Robert G Hart; Janice Pogue; Marc A Pfeffer; Stefan H Hohnloser; Raffaele De Caterina; Greg Flaker; Salim Yusuf; Stuart J Connolly
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

View more
  3 in total

Review 1.  Cerebral Amyloid Angiopathy in Stroke Medicine.

Authors:  Frank Block; Manuel Dafotakis
Journal:  Dtsch Arztebl Int       Date:  2017-01-20       Impact factor: 5.594

Review 2.  Pleiotropic effects of clopidogrel.

Authors:  Dawn S Kuszynski; D Adam Lauver
Journal:  Purinergic Signal       Date:  2022-06-09       Impact factor: 3.950

3.  Clopidogrel treatment inhibits P2Y2-Mediated constriction in the rabbit middle cerebral artery.

Authors:  Dawn S Kuszynski; Barbara D Christian; Anne M Dorrance; D Adam Lauver
Journal:  Eur J Pharmacol       Date:  2021-10-02       Impact factor: 4.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.